DIAGNOSIS AND MANAGEMENT OF COMBINED COMPLICATIONS OF CHEMOTHERAPY IN NON-HODGKIN LYMPHOMA PATIENT IN GENERAL PRACTICE

G V Kiseleva; F Islam

doi:10.17816/RFD2015237-40

Russian Family Doctor ›› 2015, Vol. 19 ›› Issue (2) : 37 -40. DOI: 10.17816/RFD2015237-40

Articles

research-article

DIAGNOSIS AND MANAGEMENT OF COMBINED COMPLICATIONS OF CHEMOTHERAPY IN NON-HODGKIN LYMPHOMA PATIENT IN GENERAL PRACTICE

Author information +

History +

PDF

Abstract

The article presents the observation of patients with toxic cardiomyopathy and oropharyngeal candidiasis after chemotherapy with anthracyclines, particularly with «doxorubicin

Keywords

non-Hodgkin lymphoma / anthracyclines / toxic cardiomyopathy / oropharyngeal candidiasis / doxorubicin

Cite this article

Download citation ▾

G V Kiseleva, F Islam. DIAGNOSIS AND MANAGEMENT OF COMBINED COMPLICATIONS OF CHEMOTHERAPY IN NON-HODGKIN LYMPHOMA PATIENT IN GENERAL PRACTICE. Russian Family Doctor, 2015, 19(2): 37-40 DOI:10.17816/RFD2015237-40

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Armitage J.O. Treatment of non-Hodgkin‘s lymphoma // N. Engl. J. Med. - 1993. - Vol. 328. - № 14. - P. 1023-1030.

[2]	Di Marco A., Cassinelli G., Arcamone F. The discovery of daunorubicin // Cancer. Treat. Rep. - 1981. - Vol. 4. - № 65. - Р. 3-8.

[3]	Lefrak E.A., Pitha J., Rosenheim S., Gottlieb J.A. A clinicopathologic analysis of adriamycin cardiotoxicity // Cancer. - 1973. - Vol. 32. - № 2. - Р. 302-314.

[4]	Von Hoff D.D., Layard M.W., Basa P., et al. Risk factors for doxorubicin-induced congestive heart failure // Ann. Intern. Med. - 1979. - Vol. 91. - № 5. - Р. 710.

[5]	Alexander J., Dainiak N., Berger H. J., et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography // N. Engl. J. Med. - 1979. - Vol. 300. - № 6. - Р. 278-283.

[6]	Buzdar A. U., Marcus C., Smith T.L., et al. Early and delayed clinical cardiotoxicity of doxorubicin // Cancer. - 1985. - Vol. 55. - № 12. - P. 2761-2765.

[7]	Ewer S.M., Ewer M.S. Cardiotoxicity profile of trastuzumab // Drug Saf. - 2008. - Vol. 31. - № 6. - Р. 459-467.

[8]	Oliveira P.J., Bjork J.A., Santos M. S. et al. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity // Toxicol. Appl. Pharmacol. - 2004. - Vol. 200. - № 2. - P. 159-168.

[9]	Spallarossa P., Garibaldi S., Altieri P. et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro // J. Mol. Cell. Cardiol. - 2004. - Vol. 37. - № 4. - P. 837-846.

[10]	Cardinale D., Colombo A., Lamantia G. et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy // J. Am. Coll. Cardiol. -2010. - Vol. 55. - № 3. - P. 213-220.

[11]	Yoon G.J., Telli M.L., Kao D.P. et al. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? // J. Am. Coll. Cardiol. -2010. - Vol. 56. - № 20. - P. 1644-1650.

[12]	Супрончук Н.В., Дмитриев В.Л., Важенин A. B., Гладков О. А. Роль доксорубицина в патогенезе ремоделирования левого желудочка и сердечной недостаточности у больных раком молочной железы // Сибирский онкологический журнал. - 2007. - № 3-4. - С. 26-31.

[13]	Yoo S.S., Lee W.H., Ha J., Choi S., Kim H.J., Kim T.H., Lee O.J. Prevalence of esophageal disorders in the subjects examined for health screening // Korean J. Gastroenterol. - 2007. - Vol. 50. - № 5. - Р. - 306-312.

[14]	Pappas P.G., Rex J.H., Sobel J.D., Filler S.G., Dismukes W.E., Walsh T.J., Edwards J.E. Practical guyde of candidiasis treatment // Clinical Infection Diseases. - 2004. - Vol. 38. - P. 161-189.

[15]	Mulcahy N. New standard of care for oral mucositis // Medscape Medical News. - October 30. - 2012. - http://www.medscape.com/viewarticle/773567. - Последнее посещение сайта 11.04.2015 г.